CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq:CAMP) granted a non-qualified stock option to purchase 5,000 shares of common stock to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term, an exercise price of $4.31, and vests over four years.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CAMP
On the day this news was published, CAMP gained 2.50%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $244.05M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum data flags one biotech peer up and one down, and sector scanner marks this as stock-specific rather than a coordinated sector move. Peer headlines today center on conferences and data presentations rather than option inducement grants.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Preclinical data update | Positive | -2.7% | New CMP-002 seizure-model data with statistically significant efficacy signals. |
| May 7 | Quarterly earnings | Positive | +2.8% | Q1 2026 results, EMA Orphan Designation, and cash runway into 2028. |
| Apr 28 | Scientific preprint | Positive | -3.8% | Preprint on regulatory RNA profiling and discovery of ASOs including CMP-002. |
| Apr 17 | Inducement option grants | Neutral | +0.5% | Inducement stock options totaling 43,000 shares for three new hires. |
| Mar 24 | Board appointment | Positive | -3.4% | Appointment of experienced biotech CFO Michael MacLean to the board. |
Positive scientific and corporate updates have sometimes seen negative or muted next-day moves, while financing- and compensation-related items have drawn relatively small reactions.
Over the last two months, CAMP4 has highlighted progress around lead candidate CMP-002 and corporate build-out. Preclinical and preprint data in April–May 2026 outlined mechanistic and seizure-model benefits, yet shares fell -3.83% and -2.67% after those updates. Q1 2026 earnings on May 7 showed $99.2M cash and runway into 2028, with a 2.76% rise. Prior inducement grants on April 15 totaling 43,000 options saw only a 0.45% move, framing today’s smaller 5,000-share grant as routine.
Regulatory & Risk Context
CAMP4 has an active Form S-3 shelf filed on November 10, 2025 to register up to $300,000,000 of securities, including an at-the-market program to sell up to $100,000,000 of common stock via Leerink Partners with up to 3.0% commission. The shelf provides flexibility to raise capital for R&D, clinical development, working capital, and potential partnerships.
Market Pulse Summary
This announcement details a routine inducement stock option grant of 5,000 shares at an exercise price of $4.31, vesting over four years under Nasdaq Listing Rule 5635(c)(4). It follows earlier, larger inducement awards in April and sits alongside recent preclinical and earnings updates that outlined cash of $99.2M and runway into 2028. Investors may monitor future clinical milestones and potential use of the $300,000,000 shelf and $100,000,000 ATM program.
Key Terms
non-qualified stock option financial
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
inducement grant financial
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on May 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 5,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Inducement Grant has a ten-year term and an exercise price per share of
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com
